Division of Gynecologic Pathology

Publications

Recent

  1. Xing D, Bakhsh S, Melnyk N, Isacson C, Ho J, Huntsman DG, Gilks CB, Ronnett BM, Horlings HM Frequent NFIB-associated Gene Rearrangement in Adenoid Cystic Carcinoma of the Vulva. Int J Gynecol Pathol. 2017 May;36(3):289-93.
  2. Ayhan A, Kuhn E, Wu RC, Ogawa H, Bahadirli-Talbott A, Mao TL, Sugimura H, Shih IM, Wang TL CCNE1 copy-number gain and overexpression identify ovarian clear cell carcinoma with a poor prognosis. Mod Pathol. 2017 Feb;30(2):297-303.
  3. Hui P, Buza N, Murphy KM, Ronnett BM. Hydatidiform Moles: Genetic Basis and Precision Diagnosis. Annu Rev Pathol. 2017 Jan 24;12:449-85.
  4. Jiang RT, Schellenbacher C, Chackerian B, Roden RB. Progress and prospects for L2-based human papillomavirus vaccines. Expert Rev Vaccines. 2016 Jul;15(7):853-62.
  5. Jung JG, Shih IM, Park JT, Gerry E, Kim TH, Ayhan A, Handschuh K, Davidson B, Fader AN, Selleri L, Wang TL. Ovarian Cancer Chemoresistance Relies on the Stem Cell Reprogramming Factor PBX1. Cancer Res. 2016 Nov 1;76(21):6351-61.
  6. Kuhn E, Wang TL, Doberstein K, Bahadirli-Talbott A, Ayhan A, Sehdev AS, Drapkin R, Kurman RJ, Shih IeM. CCNE1 amplification and centrosome number abnormality in serous tubal intraepithelial carcinoma: further evidence supporting its role as a precursor of ovarian high-grade serous carcinoma. Mod Pathol. 2016 Oct;29(10):1254-61.
  7. Lee SJ, Yang A, Wu TC, Hung CF. Immunotherapy for human papillomavirus-associated disease and cervical cancer: review of clinical and translational research. J Gynecol Oncol. 2016 Sep;27(5):e51.
  8. Soong RS, Anchoori RK, Yang B, Yang A, Tseng SH, He L, Tsai YC, Roden RB, Hung CF. RPN13/ADRM1 inhibitor reverses immunosuppression by myeloid-derived suppressor cells. Oncotarget. 2016 Oct 18;7(42):68489-502.
  9. Stolnicu S, Szekely E, Molnar C, Molnar CV, Barsan I, D'Alfonso V, Moldovan C, Zheng G, Ronnett BM*, Soslow RA*. Mature and immature solid teratomas involving uterine corpus, cervix, and ovary. Int J Gynecol Pathol 2017;36(3):222-7.
  10. Vang R, Hannibal CG, Junge J, Frederiksen K, Kjaer SK, Kurman RJ. Long-term Behavior of Serous Borderline Tumors Subdivided Into Atypical Proliferative Tumors and Noninvasive Low-grade Carcinomas: A Population-based Clinicopathologic Study of 942 Cases. Am J Surg Pathol. 2017 Jun;41(6):725-37.
  11. Veras E, Kurman RJ, Wang TL, Shih IM. PD-L1 expression in human placentas and gestational trophoblastic diseases. Int J Gynecol Pathol 2017 Mar;36(2):146-53.
  12. Xing D, Bakhsh S, Melnyk N, Isacson C, Ho J, Huntsman DG, Gilks CB, Ronnett BM, Horlings H. Frequent NFIB-associated gene rearrangement in adenoid cystic carcinoma of vulva. Int J Gynecol Pathol 2017 May;36(3):289-293.
  13. Yang A, Farmer E, Wu TC, Hung CF. Perspectives for therapeutic HPV vaccine development. J Biomed Sci 2016 Nov;23:75.
  14. Yang A, Farmer E, Lin J, Wu TC, Hung CF. The current state of therapeutic and T cell-based vaccines against human papillomaviruses. Virus Res 2017 Mar 2;231:148-65.

2016

  1. Xing D, Schoolmeester JK, Ren Z, Isacson C, Ronnett BM. Lower female genital tract tumors with adenoid cystic differentiation: P16 expression and high-risk HPV detection. Am J Surg Pathol 2016 Apr;40(4):529-36.
  2. Bynum J, Murphy KM, DeScipio C, Beierl K, Adams E, Anderson D, Vang R, Ronnett BM. Invasive Complete Hydatidiform Moles: Analysis of a Case Series With Genotyping. Int J Gynecol Pathol Int J Gynecol Pathol. 2016 Mar;35(2):134-41.
  3. Peng S, Qiu J, Yang A, Yang B, Jeang J, Wang JW, Chang YN, Brayton C, Roden RB, Hung CF, Wu TC. Optimization of heterologous DNA-prime, protein boost regimens and site of vaccination to enhance therapeutic immunity against human papillomavirus-associated disease. Cell Biosci 2016 Feb 25;6:16.
  4. Sun YY, Peng S, Han L, Qiu J, Song L, Tsai Y, Yang B, Roden RB, Trimble CL, Hung CF, Wu TC. Local HPV recombinant vaccinia boost following priming with an HPV DNA vaccine enhances local HPV-specific CD8+ T-cell-mediated tumor control in the genital tract. Clin Cancer Res 2016 Feb 1;22(3):657-69.
  5. Vang R, Levine DA, Soslow RA, Zaloudek C, Shih IeM, Kurman RJ. Molecular alterations of TP53 are a defining feature of ovarian high-grade serous carcinoma: a rereview of cases lacking TP53 mutations in The Cancer Genome Atlas ovarian study. Int J Gynecol Pathol 2016 Jan;35(1):48-55.

2015

  1. Banet N, Gown AM, Shih IM, Kay Li Q, Roden RB, Nucci MR, Cheng L, Przybycin CG, Nasseri-Nik N, Wu LS, Netto GJ, Ronnett BM, Vang R. GATA-3 expression in trophoblastic tissues: an immunohistochemical study of 445 cases, including diagnostic utility. Am J Surg Pathol 2015 Jan;39(1):101-8.
  2. Banet N, Kurman RJ. Two types of gynecological pathology. Int J Gyn Pathol Jan 2015;34(1):3-8.
  3. Huang Z, Peng S, Knoff J, Yang B, Wu TC, Hung CF. Combination of proteasome and HDAC inhibitor enhances HPV16 E7-specific CD8+ T cell immune response and antitumor effects in a preclinical cervical cancer model. J Biomed Sci. 2015 Jan 16;22:7.
  4. Kurman RJ, Banet N. Re: Article by Natalie Banet and Robert J. Kurman: Two types of ovarian cortical inclusion cysts: proposed origin and possible role in ovarian serous carcinogenesis; Int J Gynecol Pathol 2015;34:3-8. Int J Gynecol Pathol 2015 May;34(3):304-5.
  5. Morrison JC, Blanco LZ Jr, Vang R, Ronnett BM. Incidental serous tubal intraepithelial carcinoma and early invasive serous carcinoma in the nonprophylactic setting: analysis of a case series. Am J Surg Pathol. 2015 Apr;39(4):442-53.
  6. Peng S, Wang JW, Karanam B, Wang C, Huh WK, Alvarez RD, Pai SI, Hung CF, Wu TC, Roden RB. Sequential cisplatin therapy and vaccination with HPV16 E6E7L2 fusion protein in saponin adjuvant GPI-0100 for the treatment of a model HPV16+ cancer. PLoS One. 2015 Jan 5;10(1):e116389.
  7. Sun Y, Peng S, Qiu Y, Miao J, Yang B, Jeang J, Hung CF, Wu TC. Intravaginal HPV DNA vaccination with electroporation induces local CD8+ T-cell immune responses and antitumor effects against cervicovaginal tumors. Gene Ther 2015 Jul;22(7): 528-35.
  8. Wang JW, Hung CF, Huh WK, Trimble CL, Roden RB. Immunoprevention of human papillomavirus-associated malignancies. Cancer Prev Res (Phila). 2015 Feb;8(2):95-104.
  9. Wang JW, Jagu S, Wu WH, Viscidi RP, Macgregor-Das A, Fogel JM, Kwak K, Daayana S, Kitchener H, Stern PL, Gravitt PE, Trimble CL, Roden RB. Seroepidemiology of human papillomavirus 16 (HPV16) L2 and generation of L2-specific human chimeric monoclonal antibodies. Clin Vaccine Immunol. 2015 Jul;22(7):806-16.
  10. Wang JW, Jiang R, Peng S, Chang YN, Hung CF, Roden RB. Immunologic control of Mus musculus papillomavirus type 1. PLoS Pathog 2015 Oct 23;11(10):e1005243.
  11. Wang Y, Shwartz LE, Anderson D, Lin MT, Haley L, Wu RC, Vang R, Shih IeM, Kurman RJ. Molecular analysis of ovarian mucinouscarcinoma reveals different cell of origins. Oncotarget 2015 Sep 8;6(26):22949-58.
  12. Wang Y, Wu RC, Shwartz, Haley L, Lin MT, Shih IeM, Kurman RJ. Clonality analysis of combined Brenner and mucinous tumours of the ovary reveals their monoclonal origin. J Pathol. 2015 Oct;237(2):146-51.
  13. Yang B, Yang A, Peng S, Pang X, Roden RB, Wu TC, Hung CF. Co-administration with DNA encoding papillomavirus capsid proteins enhances the antitumor effects generated by therapeutic HPV DNA vaccination. Cell Biosci 2015 Jun 25;5:35.
  14. Yu Y, Gaillard S, Phillip JM, Huang TC, Pinto SM, Tessarollo NG, Zhang Z, Pandey A, Wirtz D, Ayhan A, Davidson B, Wang TL*, Shih IeM*. Inhibition of spleen tyrosine kinase potentiates paclitaxel-induced cytotoxicity in ovarian cancer cells by stabilizing microtubules. Cancer Cell 2015 Jul;28(1):82-96.